SPOP and neoplasm: Furthermore, in SPOP-WT CDX models, the combined use of SPOP-IN-6b or silmitasertib resulted in more dramatic tumor regression under olaparib treatment, with some CDX models even exhibiting complete tumor disappearance (Figure 10A), with higher levels of DNA damage and apoptosis, confirming that silmitasertib or SPOP-IN-6b indeed increased the efficacy of olaparib treatment (Figure 10B).